cvc

Taurolidine is a synthetic taurine analog with antimicrobial and anti-neoplastic actions. It displays broad bactericidal and fungicidal activity.

DCVC inhibits pathogen-stimulated TNF-α in human extra placental membranes in vitro.Target: TNF-αin vitro: DCVC inhibits pathogen stimulated cytokine release from tissue punch cultures. DCVC (5-50 μM) significantly inhibits LTA-, LPS-, and GBS-stimulated cytokine release from tissue cultures as early as 4 h (P ≤ 0.05). In contrast, TCA (up to 500 μM) does not inhibit LTA-stimulated cytokine release from tissue punches. DCVC effects on LTA-stimulated and LPS-stimulated TNF-α release from tissue punch cultures of extraplacental membranes. DCVC effects on GBS-stimulated release of pro-inflammatory cytokines from extraplacental membranes in transwell cultures. [1]. Boldenow E, et al. The trichloroethylene metabolite S-(1,2-dichlorovinyl)-l-cysteine but not trichloroacetate inhibits pathogen-stimulated TNF-α in human extraplacental membranes in vitro. Reprod Toxicol. 2015 Apr;52:1-6. [2]. Lash LH, et al. Multigenerational study of chemically induced cytotoxicity and proliferation in cultures of human proximal tubular cells. Int J Mol Sci. 2014 Nov 18;15(11):21348-65. [3]. Yoo HS, et al. Comparative analysis of the relationship between trichloroethylene metabolism and tissue-specific toxicity among inbred mouse strains: kidney effects. J Toxicol Environ Health A. 2015;78(1):32-49.

HCVcc-IN-1, a derivative of benzothiazole-2-thiophene S-glycoside, exhibits low toxicity and antiviral properties [1].

AcLys-PABC-VC-Aur0101 is a drug-linker conjugate for anti-CXCR4 ADC, exhibiting potent antitumor activity and comprising the auristatin microtubule inhibitor Aur0101, connected through the cleavable linker AcLys-PABC-VC[1].

MC-Val-Cit-PAB-tubulysin5a is a drug-linker conjugate for ADC with potent antitumor activity by using tubulysin5a (a tubulin inhibitor), linked via the ADC linker MC-Val-Cit-PAB.

MC-VC-PABC-DNA31 is a drug-linker conjugate designed for Antibody-Drug Conjugates (ADC), exhibiting potent antitumor activity. It utilizes DNA31, a powerful inhibitor of RNA polymerase, connected via the MC-VC-PABC ADC linker.

MC-VC-PABC-Aur0101 is a potent anticancer drug-linker conjugate for Antibody-Drug Conjugates (ADCs), incorporating Aur0101, an auristatin microtubule inhibitor, linked via the MC-VC-PABC linker to boost antitumor efficacy.

SC-VC-PAB-DM1 is a drug-linker conjugate used in Antibody-Drug Conjugates (ADC), combining DM1 (Mertansine, a tubulin inhibitor) with the SC-VC-PAB[1] ADC linker to deliver potent antitumor activity.

SC-VC-PAB-MMAE is a potent antitumor drug-linker conjugate for antibody-drug conjugates (ADCs), consisting of the anti-mitotic agent monomethyl auristatin E (MMAE, a tubulin inhibitor) linked via the cleavable linker SC-VC-PAB[1].

MAC-VC-PABC-ST7612AA1 is a part of antibody drug conjugates (ADCs) charged with HDAC inhibitor by a linker, shows antitumor activity[1].

MC-VC-PAB-Azide is a cleavable ADC linker utilized in the synthesis of antibody-drug conjugates (ADC).

LacNAc-VC-PAB-MMAE is a component of an antibody-drug conjugate (ADC). It is assembled onto the N-glycosylation site of Trastuzumab through WT Endo-S2.

MC-VC-PAB-NH2 is a cleavable linker crucial in ADC (antibody-drug conjugate) synthesis. It facilitates the attachment of cytotoxic drugs to antibodies, allowing targeted delivery to specific cells or proteins. Its cleavable nature ensures controlled drug release, thereby optimizing the effectiveness of ADCs.

MC-vc-PAB-Tubulysin M is a conjugate comprising a cleavable ADC linker (MC-vc-PAB) and the cytotoxic tubulin inhibitor Tubulysin M, which inhibits tubulin polymerization, leading to cell cycle arrest and apoptosis.

Mc-VC-PAB-SN38 consists of a cleavable ADC linker (Mc-VC-PAB) and SN38, which is part of an antibody-coupled reactive molecule commonly used to synthesize antibody-coupled reactive molecules (ADCs) that target sites of action.

MC-VC-PABC-amide-PEG1-CH2-CC-885 is an Antibody-Drug Conjugate (ADC) that employs a protein-degrading agent (protac molecular glue, etc.).

VCMMAE (mc-vc-PAB-MMAE) is a drug-linker conjugate for ADC with potent antitumor activity.

MC-VC-PAB-MMAD is a conjugate for antibody-drug conjugates (ADCs) that exhibits potent antitumor activity by employing MMAD, a powerful tubulin inhibitor, connected through the cleavable ADC linker MC-VC-PAB [1].

MC-VC-PABC-SP 141 is a potent antitumor conjugate for antibody-drug conjugation (ADC), featuring SP 141, a robust MDM2 inhibitor, connected through the cleavable linker [MC-VC-PABC], facilitating targeted cancer therapy.

HCV Core Protein (59-68) is a peptide containing residues 59-68 from the core protein of the Hepatitis C virus (HCV) [1].

HCV Core Protein (107-114), identified as the binding site within the region 101-118, is a minimally immunogenic fragment of the primary linear HCV core regions. This segment, comprising two residues that vary between genotypes I/II and III/VI, represents a potential focal point for the dissemination of HCV serotypes [1].

MC-VC-PAB-NH2 TFA is a degradable ADC linker for synthesizing antibody-drug conjugates (ADCs).

GGGDTDTC-Mc-vc-PAB-MMAE is a drug-linker conjugate for antibody-drug conjugates (ADCs), containing monomethyl auristatin E (MMAE), a tubulin inhibitor, as the cytotoxic component [1].

MC-VC-PAB-Cyclohexanediamine-Thailanstatin A, a spliceostatin analog and drug-linker conjugate for antibody-drug conjugates (ADC), comprises the cytotoxic component Thailanstatin A and the cleavable linker (MC-vc-PAB). This compound is utilized in the synthesis of ADCs [1].